Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4602 for Injection in Advanced Solid Tumors (Phase II)
CTR20244423Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Nov 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SHR-4602 in Nonhematologic neoplasms, sponsored by Suzhou Shengdiya Biopharmaceuticals. Primary endpoint: Objective Response Rate (ORR). Started Nov 2024; status: active.
02
Drugs
SHR-4602
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20244423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244423.